India Pharma Outlook Team | Monday, 20 July 2026
The US Cancer Market has moved a step closer for Alembic Pharma and Natco Pharma after the companies secured a key regulatory milestone.
Natco received USFDA tentative approval for its ANDA covering Olaparib Tablets in 100 mg and 150 mg strengths. Alembic will exclusively market and distribute the product in the United States.
The development brings both companies closer to entering the US Cancer Market, valued at nearly USD 1.4 billion.
The approval covers the generic version of Lynparza, a cancer medicine developed by AstraZeneca. The drug is used to treat certain patients with ovarian, breast, pancreatic, and prostate cancers. Although the approval is tentative, it confirms the product meets the USFDA's quality, safety, and manufacturing standards.
Natco Pharma filed the abbreviated new drug application for generic Olaparib tablets. The company received tentative approval from the USFDA after meeting all regulatory requirements.
However, the product cannot be sold immediately.
Commercial launch will begin only after patent and exclusivity protections for the branded drug expire.
Under the partnership agreement:
Tentative approval is an important regulatory step. It allows companies to prepare for launch while waiting for legal barriers to end.
Also Read: The Strategic Role of Regional Corridors in Future-Ready MedTech
The latest approval gives both companies access to a large future opportunity. According to IQVIA data, annual sales of Olaparib tablets in the United States reached nearly USD 1.4 billion for the 12 months ending March 2026.
The oncology segment remains one of the fastest-growing areas in the pharmaceutical industry. Generic versions of high-value cancer drugs often see strong demand after launch.
This approval also strengthens Alembic Pharma's presence in regulated markets. At the same time, it expands Natco Pharma's oncology portfolio in the United States.
The approval does not generate immediate revenue. Final marketing approval will depend on patent expiry and exclusivity timelines.
Still, the development is positive for both companies.
Key takeaways include:
Once final approval is granted, Natco and Alembic will be positioned to launch a lower-cost alternative to Lynparza. That could help both companies strengthen their foothold in one of the world's largest pharmaceutical markets.
